C. Jean Grover, Thalidomide survivor and activist.Photo:Anjelica Jardiel
Anjelica Jardiel
In November 1961, Ann Morris (her name has been changed to protect her privacy) went to her ob-gyn because she was feeling nauseous. Suspecting pregnancy, the doctor gave Morris an unmarked sample of a new drug to ease her symptoms. Morris was under the impression they were vitamins.
Nine months later, she gave birth to a daughter, C. Jean Grover, who was born with severely shortened arms and legs, a rare condition known as phocomelia. She was also diagnosed with bilateral PFFD, which causes deformities in the hip, leaving one leg shorter than the other. Both conditions are specifically associated with thalidomide.
The drug thalidomide first surfaced in Europe during the 1950s. It was initially used as a sedative, but doctors discovered it was also an effective treatment for colds, headaches, nausea — and morning sickness.
It wasn’t until 1961, after tens of thousands of pregnant women had been prescribed the drug abroad, that thalidomide was definitively linked to infant deaths and severe birth defects in an estimated 10,000 children in over 46 countries — and taken off the market.
But Morris’ doctors at Cincinnati’s Jewish Hospital failed to make that connection when Grover was born. They advised that she be placed in foster care because they said she was unlikely to survive.
“It was like out of sight, out of mind,” Grover, now 60, tells PEOPLE in this week’s issue.
C. Jean Grover when she was 3 years old.John T. Powell
John T. Powell
Never miss a story — sign up forPEOPLE’s free daily newsletterto stay up-to-date on the best of what PEOPLE has to offer, from juicy celebrity news to compelling human interest stories.
“Other countries have provided assistance to survivors,” Grover says. “But the U.S. has done nothing because it was so well swept under the rug.”
According to author Vanderbes, the drug was being distributed in the U.S. under the guise of clinical trials. Although the FDA learned about the birth defects in 1961, Vanderbes’s research shows that the agency didn’t move to recall the drug until the summer of 1962.
C. Jean Grover at home in Rochester, New York, July 9, 2023.Anjelica Jardiel
As she grew up, Grover learned to walk using prostheses on both legs; she has never needed arm prostheses. She went on to graduate from college, launch a successful career in graphic design and marketing, and raise four children of her own.
She started using a scooter after worrying about falling while pregnant, and has learned to compensate and manage her day-to-day challenges in various ways. Still, it’s a constant struggle.
“I’m able to contort my body around to dress myself relatively independently now,” says Grover, who drives a van with hand controls and a lift. “But make no mistake, I’m pretty messed up. I can laugh about it, but I do have a lot of things that I work around every day.”
Today, she serves as a board member forU.S. Thalidomide Survivors, which aims to raise awareness and secure government aid and health care support for survivors in their later years. The organization — which released the documentaryThalidomide in the USA: The Forgotten Survivors—is planning to meet with members of Congress in September about securing assistance for survivors across the country.
“The federal government dropped this case without ever fully investigating the drug companies and what they had done and how wide the distribution had been,” says Grover. “This was the entire system letting us down.”
For the full story on C. Jean Grover, pick up the latest issue of PEOPLE, on newsstands Friday, or subscribehere.
source: people.com
